Primary Site >> Colorectal Cancer
Gene >> AES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. PMID: 7707120 |
Ref: Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. PMID: 8874326 |
Ref: Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. PMID: 9829586 |
Ref: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. PMID: 12409327 |
Ref: Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. PMID: 17241512 |
Ref: Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. PMID: 17194911 Ref: Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. PMID: 17289896 |
Ref: A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. PMID: 17986625 Ref: Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. PMID: 18425418 Ref: Potential regional differences for the tolerability profiles of fluoropyrimidines. PMID: 18445840 Ref: A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. PMID: 18650196 |
Ref: Clinical comparison of QOL and adverse events during postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer. PMID: 19288009 Ref: Health utility scores of colorectal cancer based on societal preference in Japan. PMID: 19626462 |
Ref: Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. PMID: 20498386 |
Ref: Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. PMID: 21251616 Ref: Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. PMID: 21737652 Ref: Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. PMID: 21900113 Ref: Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. PMID: 22027708 |
Ref: Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. PMID: 21828378 Ref: Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. PMID: 22294436 Ref: First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study. PMID: 22348174 Ref: Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. PMID: 22415232 Ref: A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. PMID: 22421192 Ref: Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. PMID: 22612854 Ref: Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. PMID: 22614981 |
Ref: Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. PMID: 23096768 Ref: XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. PMID: 23100174 Ref: A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer. PMID: 23108698 Ref: Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. PMID: 23645758 Ref: A pilot study on record reviewing with a priori patient selection. PMID: 23872292 Ref: [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy]. PMID: 23985254 Ref: A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. PMID: 24075777 Ref: Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. PMID: 24155628 |
Ref: Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. PMID: 24097815 Ref: Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. PMID: 24377572 Ref: Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. PMID: 24390424 Ref: Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). PMID: 24594119 Ref: A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. PMID: 24604265 Ref: Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. PMID: 25012508 Ref: Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. PMID: 25223744 Ref: DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). PMID: 25381393 Ref: A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis. PMID: 26158159 |
Ref: Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO. PMID: 25432929 Ref: Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. PMID: 25466509 Ref: A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. PMID: 25529193 Ref: DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. PMID: 25782327 Ref: Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. PMID: 26034219 Ref: Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. PMID: 26109816 Ref: Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. PMID: 26160607 Ref: Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. PMID: 26189513 Ref: Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. PMID: 26446234 Ref: Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry. PMID: 26471890 Ref: A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. PMID: 26490655 Ref: Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. PMID: 26497654 |
Ref: Characterization of Aes nuclear foci in colorectal cancer cells. PMID: 26229111 Ref: Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan. PMID: 26771865 Ref: DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. PMID: 26794347 Ref: A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. PMID: 27025608 Ref: Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. PMID: 27463016 Ref: Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. PMID: 27528724 Ref: Expression of metastasis suppressor gene AES driven by a Yin Yang (YY) element in a CpG island promoter and transcription factor YY2. PMID: 27561171 |
Ref: A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. PMID: 27650277 Ref: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. PMID: 28152546 Ref: Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer. PMID: 28178391 Ref: The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. PMID: 28415706 Ref: Oral versus intravenous fluoropyrimidines for colorectal cancer. PMID: 28752564 Ref: Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. PMID: 28932193 Ref: Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer. PMID: 29108334 Ref: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PMID: 29284010 |
Ref: Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. PMID: 29249584 Ref: Patient-reported symptoms and stepwise symptom management in patients on epidermal growth factor inhibitors: A retrospective, descriptive cohort study. PMID: 29314360 Ref: Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study). PMID: 29484450 Ref: Associations of Genetic Variations in MicroRNA Seed Regions With Acute Adverse Events and Survival in Patients With Rectal Cancer Receiving Postoperative Chemoradiation Therapy. PMID: 29485044 Ref: Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. PMID: 29528991 Ref: Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer. PMID: 29663379 Ref: LncRNA HOTAIR is a Prognostic Biomarker for the Proliferation and Chemoresistance of Colorectal Cancer via MiR-203a-3p-Mediated Wnt/ss-Catenin Signaling Pathway. PMID: 29680837 Ref: Regorafenib: A Review in Metastatic Colorectal Cancer. PMID: 29943375 Ref: Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. PMID: 30010751 Ref: Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials. PMID: 30323618 |